Figure 2.
Figure 2. Distribution of the 257 patients with NRAS mutations within cytogenetic subgroups. Significant differences compared with the cohort of 2245 patients with NRASwt and available cytogenetics are labeled with asterisks. Normal karyotype, 109 of 1198 (9.1%); t(15;17), 2 of 102 (2%) (*P = .005); t(8;21), 13 of 132 (9.8%); inv(16), 50 of 133 (37.6%) (**P < .001); 11q23/MLL, 3 of 77 (3.9%) (***P = .062); inv(3)t(3;3), 11 of 41 (26.8%) (****P = .001); complex typical karyotype37, 4 of 258 (1.6%) (*****P = .001); complex atypical karyotype37, 7 of 56 (12.5%); +8, 18 of 122 (14.8%); 5q–/–5, 4 of 24 (16.7%); 7q–/–7, 4 of 58 (6.9%); other aberrations, 32 of 301 (10.6%); total, 257 of 2502 (10.3%).

Distribution of the 257 patients with NRAS mutations within cytogenetic subgroups. Significant differences compared with the cohort of 2245 patients with NRASwt and available cytogenetics are labeled with asterisks. Normal karyotype, 109 of 1198 (9.1%); t(15;17), 2 of 102 (2%) (*P = .005); t(8;21), 13 of 132 (9.8%); inv(16), 50 of 133 (37.6%) (**P < .001); 11q23/MLL, 3 of 77 (3.9%) (***P = .062); inv(3)t(3;3), 11 of 41 (26.8%) (****P = .001); complex typical karyotype37 , 4 of 258 (1.6%) (*****P = .001); complex atypical karyotype37 , 7 of 56 (12.5%); +8, 18 of 122 (14.8%); 5q–/–5, 4 of 24 (16.7%); 7q–/–7, 4 of 58 (6.9%); other aberrations, 32 of 301 (10.6%); total, 257 of 2502 (10.3%).

Close Modal

or Create an Account

Close Modal
Close Modal